Aptorum Group Ltd (APM) is a cutting-edge biopharmaceutical company committed to discovering, developing, and commercializing therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers (including orphan oncology indications). The company operates primarily in Hong Kong and the United States, and is listed on the NASDAQ under the symbol "APM".
Founded in 2010, Aptorum Group Ltd is dedicated to the advancement of a broad range of innovative clinical and pre-clinical products. It actively pursues therapeutic and diagnostic projects in metabolic diseases, neurology, infectious diseases, and other disease areas. To assist the advancement of its pipeline, the company also focuses on various technologies, including Smart-ACT™, a drug discovery platform which allows the identification of targeted therapies based on genetic similarities among different patient populations.
Through strategic partnerships and acquisitions, Aptorum Group has expanded its product portfolio, which now includes over 15 therapeutic candidates in different stages of development. This diversified portfolio echoes the company's belief in developing and commercializing effective therapeutic solutions across various health sectors to alleviate human suffering.
Aptorum Group also works towards promoting knowledge and understanding around unmet medical needs and innovative therapies. It is proactive in clinical and regulatory research, and is committed to meeting the highest ethical, medical, and scientific standards. A case in point is its unique approach to research and development, where it enlists the help of leading researchers and clinicians from around the world to ensure drug candidates have the maximum potential for success.
Moreover, Aptorum Group notably established A*STAR, a non-profit subsidiary to promote clinical research in areas exceptionally underserved. This entity pursues both innovative and established therapies and is dedicated to improving patient outcomes, particularly in life-threatening conditions.
Aptorum Group's dedication to life sciences research and its commitment to addressing unmet medical needs have positioned it as a trusted and promising player in the biopharmaceutical industry. Its aggressive R&D strategy and broad product portfolio indicate its potential for significant growth and its pledge to substantially contribute to global health solutions.